A Prospective Multi-modal Cohort Study of Local Treatment-related Toxicities and Quality of Life in Chinese Breast Cancer Patients (PERSEVERE)

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

This study, called PERSEVERE, examines how local treatment for early breast cancer affects people's health and daily lives over time. People who join the study will have early-stage breast cancer and receive treatment such as surgery and other therapies that are used before or after surgery. The study does not include people with late-stage (metastatic) breast cancer. Researchers want to learn about short- and long-term side effects that can happen during or after treatment. These may include tiredness, trouble sleeping, emotional distress, pain, or changes in heart or lung function. The study also looks at how these effects impact participants' quality of life. Participants will be asked to complete surveys about how they feel. They will also have health checks, such as heart tests, lung function tests, and blood samples. Tissue samples from surgery will also be collected. The goal is to understand better how different people respond to breast cancer treatment and find ways to support long-term recovery.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: t
View:

• Women aged 18 years or older

• Diagnosed with stage I, II, or III invasive breast cancer confirmed by pathology or cytology

• No signs of metastatic disease (cancer that has spread to other parts of the body)

• Scheduled to receive local treatment, including:

⁃ Surgery

⁃ And/or neoadjuvant or adjuvant therapy such as chemotherapy, radiation, hormone therapy, or targeted therapy

• Willing and able to complete health questionnaires and attend follow-up visits

• Has given written informed consent to join the study

Locations
Other Locations
China
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING
Beijing
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
ACTIVE_NOT_RECRUITING
Shenzhen
Shanxi Cancer Hospital
ACTIVE_NOT_RECRUITING
Taiyuan
Contact Information
Primary
Zheng Qu, MD
quzheng1237@gmail.com
+8615010998669
Time Frame
Start Date: 2025-04-07
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 3000
Treatments
Early-Stage Breast Cancer Patients Receiving Local Therapy
This group includes people diagnosed with stage I to III breast cancer who are receiving local therapy with curative intent. Local therapy in this study includes surgery, as well as systemic treatments given before or after surgery, such as:~Neoadjuvant therapy (for example, chemotherapy or targeted therapy given before surgery)~Adjuvant therapy (for example, chemotherapy, radiotherapy, endocrine therapy, or targeted therapy given after surgery)~This is an observational study. There is no experimental intervention. All participants will undergo baseline assessments, including clinical evaluations, laboratory tests, patient-reported outcome questionnaires, and biospecimen collection. Participants will then be followed over time to monitor treatment-related toxicities and changes in quality of life.
Related Therapeutic Areas
Sponsors
Leads: FangYi

This content was sourced from clinicaltrials.gov